Sclerostin Blood Levels Before and After Kidney Transplantation
Background/Aims: Sclerostin is secreted by osteocytes. As a circulating inhibitor of the Wnt-signaling pathway it inhibits bone formation and contributes to the development of osteoporosis. Sclerostin levels are elevated in patients with chronic kidney disease and end-stage renal disease. Since data...
Main Authors: | Marco Bonani, Daniel Rodriguez, Thomas Fehr, Nilufar Mohebbi, Jens Brockmann, Markus Blum, Nicole Graf, Diana Frey, Rudolf P. Wüthrich |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2014-07-01
|
Series: | Kidney & Blood Pressure Research |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/355781 |
Similar Items
-
Serum sclerostin in rheumatoid-induced osteoporosis
by: Ola Gharbia, et al.
Published: (2020-07-01) -
Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab
by: Claudia Kobel, et al.
Published: (2019-10-01) -
Drug discovery of sclerostin inhibitors
by: Sifan Yu, et al.
Published: (2022-05-01) -
Serum Sclerostin Level Is Negatively Associated with Bone Mineral Density in Hemodialysis Patients
by: Jing-Wun Lu, et al.
Published: (2022-03-01) -
Predictive Power of Bone Turnover Biomarkers to Estimate Bone Mineral Density after Kidney Transplantation with or without Denosumab: A post hoc Analysis of the POSTOP Study
by: Nadine Heimgartner, et al.
Published: (2020-09-01)